Placebo for PRAX-628

DRUG3 trials

Sponsors

Praxis Precision Medicines Inc., Praxis Precision Medicines Inc., Praxis Precision Medicines Inc.

Conditions

Focal EpilepsyIPS induced photoparoxysmal electroencephalogram response (IPS-induced PPR) in participants with epilepsy and IPS-induced PPR

Phase 2

A Phase 2, Single-Blind, Placebo-Controlled, Fixed-Sequence Design Trial to Evaluate the Photoparoxysmal Electroencephalogram Response, Safety, Tolerability, and Pharmacokinetics of PRAX-628 in Participants with Epilepsy and a Photoparoxysmal Electroencephalogram Response to Intermittent Photic Stimulation

CompletedCTIS2023-504803-10-00

Praxis Precision Medicines Inc., Praxis Precision Medicines Inc.IPS induced photoparoxysmal electroencephalogram response (IPS-induced PPR) in participants with epilepsy and IPS-induced PPR

Start: 2023-06-15End: 2024-03-14Target: 12Updated: 2024-03-15

A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1)

RecruitingCTIS2024-514559-13-00

Praxis Precision Medicines Inc.Focal Epilepsy

Start: 2024-11-26Target: 170Updated: 2025-12-22

Phase 3

A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures

Not yet recruitingCTIS2025-524038-24-00

Praxis Precision Medicines Inc.Focal Epilepsy

Target: 12Updated: 2026-04-10